M. Horn

Serum neurofilament light chain (sNfL) values in a large cross-sectional population of children with asymptomatic to moderate COVID-19

J. Kuhle, G. Puchner, D. Peterhoff, 2021, Journal of Neurology.

Safety, reactogenicity, and immunogenicity of a 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine in healthy toddlers: results from a phase I, randomized trial

D. Borys, U. Behre, M. Horn, 2020, Human vaccines & immunotherapeutics.

Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults

Ping Li, E. Neumeier, F. Martinón-Torres, 2018, BMC Infectious Diseases.

Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib and PHiD-CV When Coadministered With MenACWY-TT in Infants: Results of an Open, Randomized Trial

T. Fischbach, A. Carmona Martínez, J. M. Merino Arribas, 2018, The Pediatric infectious disease journal.

Safety and Immunogenicity of the Quadrivalent Meningococcal Serogroups A, C, W and Y Tetanus Toxoid Conjugate Vaccine Coadministered With Routine Childhood Vaccines in European Infants: An Open, Randomized Trial

T. Fischbach, A. Carmona Martínez, J. M. Merino Arribas, 2017, The Pediatric infectious disease journal.

Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.

L. Szenborn, R. Prymula, A. Carmona Martínez, 2019, Vaccine.

Immunogenicity and Safety of Porcine Circovirus-Free Human Rotavirus Vaccine in Healthy Infants: A Phase 3 Randomized Trial

N. Chiu, Li-Min Huang, J. García-Sicilia, 2020, The Journal of infectious diseases.

Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9–14 Years: A Randomized Trial

P. Hillemanns, C. Giaquinto, T. Puthanakit, 2017, The Journal of infectious diseases.

Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9–14 Years Versus a 3-Dose Regimen in Women Aged 15–25 Years

C. Giaquinto, T. Puthanakit, C. Chiu, 2016, The Journal of infectious diseases.